Wang Xinxin, Wang Yunhan, Yang Lei, Zhang Yi, Yang Li
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
School of Life Sciences, Zhengzhou University, Zhengzhou, China.
Front Immunol. 2025 Apr 2;16:1550893. doi: 10.3389/fimmu.2025.1550893. eCollection 2025.
Triggering receptors expressed on myeloid cells 2 (TREM2), an immune receptor expressed on myeloid cells, has garnered considerable attention in recent years due to its role in unique signaling pathways and diverse biological functions, including phagocytosis, lipid metabolism, cell survival, and inflammatory responses. Although TREM2 is expressed in various cell types, such as macrophages, dendritic cells (DCs), osteoclasts, and others, where it exhibits context-dependent functional characteristics, it is mainly expressed in macrophages. Notably, TREM2 is implicated in the development and progression of multiple diseases, playing dual and often opposing roles in noncancerous diseases and cancers. This review aims to highlight the pivotal role of TREM2 in macrophages and immune-related diseases, elucidate its underlying mechanisms of action, explore its potential as a clinical diagnostic and prognostic marker, and propose therapeutic strategies targeting TREM2 based on current clinical trial data, providing comprehensive guidance and references for clinical practice.
髓系细胞表达的触发受体2(TREM2)是一种在髓系细胞上表达的免疫受体,近年来因其在独特信号通路和多种生物学功能(包括吞噬作用、脂质代谢、细胞存活和炎症反应)中的作用而备受关注。尽管TREM2在多种细胞类型中表达,如巨噬细胞、树突状细胞(DC)、破骨细胞等,且在这些细胞中表现出依赖于环境的功能特征,但它主要在巨噬细胞中表达。值得注意的是,TREM2与多种疾病的发生和发展有关,在非癌性疾病和癌症中发挥着双重且往往相反的作用。本综述旨在强调TREM2在巨噬细胞和免疫相关疾病中的关键作用,阐明其潜在作用机制,探索其作为临床诊断和预后标志物的潜力,并根据当前临床试验数据提出针对TREM2的治疗策略,为临床实践提供全面指导和参考。